DAX19.060 -0,7%ESt504.751 -0,8%MSCIW3.739 ±0,0%Dow43.269 -0,3%Nas18.987 +1,0%Bitcoin86.672 +1,4%Euro1,0598 ±0,0%Öl73,30 +0,2%Gold2.634 +0,1%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
NVIDIA 918422 Rheinmetall 703000 Tesla A1CX3T Super Micro Computer A40MRM Bayer BAY001 Palantir A2QA4J MicroStrategy 722713 EVOTEC 566480 Siemens Energy ENER6Y thyssenkrupp 750000 Amazon 906866 Volkswagen (VW) vz. 766403 Coinbase A2QP7J Mercedes-Benz Group (ex Daimler) 710000 RENK RENK73
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX beendet Handel knapp über 19.000 Punkten -- US-Börsen uneinheitlich -- thyssenkrupp: Milliardenverlust -- Rivian-CFO will sich von Millionen Rivian-Aktien trennen -- Super Micro, Xpeng im Fokus
Top News
Gewinne in New York: NASDAQ Composite letztendlich auf grünem Terrain Gewinne in New York: NASDAQ Composite letztendlich auf grünem Terrain
Gewinne in New York: NASDAQ 100 beendet den Dienstagshandel in der Gewinnzone Gewinne in New York: NASDAQ 100 beendet den Dienstagshandel in der Gewinnzone
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil
US-Wahl treibt Bitcoin über 90.000 USD. Wie Anleger vom neuen Krypto-Hype profitieren können.

Merck Aktie

NeuKaufenVerkaufen
Merck Aktien-Sparplan
90,80 EUR -0,20 EUR -0,22 %
STU
96,70 USD +0,16 USD +0,17 %
nachbörslich
BTT
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.230,14 Mrd. EUR

KGV760,78Div. Rendite2,72%

WKNA0YD8Q

ISINUS58933Y1055

SymbolMRK

Merck Aktien News

DatumMeistgelesen
PR NewswireCanada's Drug Agency Recommends WINREVAIR® (sotatercept) for Reimbursement
PR NewswireCanada's Drug Agency Recommends WINREVAIR® (sotatercept) for Reimbursement
PR NewswireMerck Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) successfully complete negotiations for WELIREG® (belzutifan)
Wer­bungMerck-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
PR NewswireMerck Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) successfully complete negotiations for WELIREG® (belzutifan)
PR NewswireWINREVAIR® (sotatercept) is now authorized for use in Canada for Adults with Pulmonary Arterial Hypertension
PR NewswireWINREVAIR® (sotatercept) is now authorized for use in Canada for Adults with Pulmonary Arterial Hypertension
PR NewswireHealth Canada Approves KEYTRUDA® for the treatment of adult patients with unresectable locally advanced or metastatic urothelial cancer (mUC) with no prior systemic therapy for mUC, in combination...
PR NewswireHealth Canada Approves KEYTRUDA® for the treatment of adult patients with unresectable locally advanced or metastatic urothelial cancer (mUC) with no prior systemic therapy for mUC, in combination...
PR NewswireElanco Completes Sale of Aqua Business
PR NewswireASNA and Athinia® collaborate to boost semiconductor manufacturing yields through improved data sharing and traceability of subcomponent parts
PR NewswireHealth Canada Approves KEYTRUDA® for adult patients with locally advanced unresectable or metastatic biliary tract carcinoma, in combination with gemcitabine-based chemotherapy
PR NewswireHealth Canada Approves KEYTRUDA® for adult patients with locally advanced unresectable or metastatic biliary tract carcinoma, in combination with gemcitabine-based chemotherapy
PR NewswireHealth Canada Approves KEYTRUDA® as a first-line treatment for adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcino...
PR NewswireHealth Canada Approves KEYTRUDA® as a first-line treatment for adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcino...
PR NewswireFarmSee Ltd Announces the Completion of a Minority Investment in its Swine Monitoring Platform
PR NewswireHealth Canada Approves KEYTRUDA® in combination with trastuzumab and chemotherapy, as a first-line treatment for patients with locally advanced unresectable or metastatic HER2-positive gastric or ...
PR NewswireHealth Canada Approves KEYTRUDA® in combination with trastuzumab and chemotherapy, as a first-line treatment for patients with locally advanced unresectable or metastatic HER2-positive gastric or ...
PR NewswireMERCK CANADA ANNOUNCES COLLABORATION WITH VECTOR INSTITUTE TO FURTHER ADVANCE ITS ARTIFICIAL INTELLIGENCE CAPABILITIES AND DRIVE INNOVATION IN HEALTHCARE
PR NewswireMERCK CANADA ANNOUNCES COLLABORATION WITH VECTOR INSTITUTE TO FURTHER ADVANCE ITS ARTIFICIAL INTELLIGENCE CAPABILITIES AND DRIVE INNOVATION IN HEALTHCARE
PR NewswireElanco Announces Sale of Aqua Business for $1.3 Billion
PR NewswireMerck Animal Health's Fourth Veterinary Wellbeing Study Indicates Progress in Addressing Mental Health Challenges Among Veterinary Teams
PR NewswireKEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Receive Public Listing for Patients with Advanced Endometrial Carcinoma (EC) that is not MSI-H or dMMR
PR NewswireKEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Receive Public Listing for Patients with Advanced Endometrial Carcinoma (EC) that is not MSI-H or dMMR
MyDividendsPharmakonzern Merck erhöht die Dividende das 13. Jahr in Folge
PR NewswireKEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) is Available for the First-Line Treatment of Adult Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)
PR NewswireKEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) is Available for the First-Line Treatment of Adult Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)
MyDividendsPharmakonzern Merck & Co. zahlt Dividende aus
PR NewswireAnixa Biosciences Announces Opening of Enrollment for Keytruda® Arm in Ongoing Breast Cancer Vaccine Clinical Trial
MyDividendsPharmakonzern Merck hält die Dividende konstant
PR NewswireData Vault Holdings, Inc. and p-Chip Corporation to Connect Platforms through Enabling IP Licensing Agreement
MyDividendsPharmakonzern Merck zahlt Dividende für das dritte Quartal
MyDividendsPharmakonzern Merck gibt Dividende bekannt
PR NewswireMerck Selects Perceiv AI for Inaugural Digital Sciences Studio Cohort
PR NewswireMerck Selects Perceiv AI for Inaugural Digital Sciences Studio Cohort
MyDividendsPharmakonzern Merck zahlt Dividende an die Investoren aus
PR NewswireAstellas, Seagen and Merck Announce FDA Acceptance of Supplemental Biologics License Applications for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment ...
MyDividendsPharmakonzern Merck steigert die Dividende das zwölfte Jahr in Folge
RSSForm 4 310158
PR NewswireVeeva und Merck gehen eine langfristige strategische Partnerschaft ein
PR NewswireVeeva and Merck Form Long-Term Strategic Partnership

Merck News

Merck News: auf dieser Seite finden Sie alle Merck News und Nachrichten zur Merck Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Merck News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Merck News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.